Corbus Pharmaceuticals Holding
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.68
- Today's High:
- $8.975
- Open Price:
- $8.05
- 52W Low:
- $2.11
- 52W High:
- $16.659
- Prev. Close:
- $8.05
- Volume:
- 236914
Company Statistics
- Market Cap.:
- $39.57 million
- Book Value:
- 7.909
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-16136826
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.02%
- Return on Equity TTM:
- -82.95%
Company Profile
Corbus Pharmaceuticals Holding had its IPO on 2014-11-11 under the ticker symbol CRBP.
The company operates in the Healthcare sector and Biotechnology industry. Corbus Pharmaceuticals Holding has a staff strength of 33 employees.
Stock update
Shares of Corbus Pharmaceuticals Holding opened at $8.05 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $7.68 - $8.98, and closed at $8.83.
This is a +9.69% increase from the previous day's closing price.
A total volume of 236,914 shares were traded at the close of the day’s session.
In the last one week, shares of Corbus Pharmaceuticals Holding have increased by +32.58%.
Corbus Pharmaceuticals Holding's Key Ratios
Corbus Pharmaceuticals Holding has a market cap of $39.57 million, indicating a price to book ratio of 0.3704 and a price to sales ratio of 163.3187.
In the last 12-months Corbus Pharmaceuticals Holding’s revenue was $0 with a gross profit of $-16136826 and an EBITDA of $-34072448. The EBITDA ratio measures Corbus Pharmaceuticals Holding's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Corbus Pharmaceuticals Holding’s operating margin was 0% while its return on assets stood at -25.02% with a return of equity of -82.95%.
In Q4, Corbus Pharmaceuticals Holding’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Corbus Pharmaceuticals Holding’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-11.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Corbus Pharmaceuticals Holding’s profitability.
Corbus Pharmaceuticals Holding stock is trading at a EV to sales ratio of 8.2564 and a EV to EBITDA ratio of 0.7761. Its price to sales ratio in the trailing 12-months stood at 163.3187.
Corbus Pharmaceuticals Holding stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $66.31 million
- Total Liabilities
- $12.64 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $13435.55
- Dividend Payout Ratio
- 0%
Corbus Pharmaceuticals Holding ended 2023 with $66.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $66.31 million while shareholder equity stood at $32.99 million.
Corbus Pharmaceuticals Holding ended 2023 with $0 in deferred long-term liabilities, $12.64 million in other current liabilities, 417.00 in common stock, $-392080667.00 in retained earnings and $0 in goodwill. Its cash balance stood at $17.00 million and cash and short-term investments were $59.20 million. The company’s total short-term debt was $4,429,855 while long-term debt stood at $15.98 million.
Corbus Pharmaceuticals Holding’s total current assets stands at $60.18 million while long-term investments were $0 and short-term investments were $42.19 million. Its net receivables were $0 compared to accounts payable of $2.17 million and inventory worth $0.
In 2023, Corbus Pharmaceuticals Holding's operating cash flow was $0 while its capital expenditure stood at $13435.55.
Comparatively, Corbus Pharmaceuticals Holding paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $8.83
- 52-Week High
- $16.659
- 52-Week Low
- $2.11
- Analyst Target Price
- $120
Corbus Pharmaceuticals Holding stock is currently trading at $8.83 per share. It touched a 52-week high of $16.659 and a 52-week low of $16.659. Analysts tracking the stock have a 12-month average target price of $120.
Its 50-day moving average was $4.38 and 200-day moving average was $5.27 The short ratio stood at 1.26 indicating a short percent outstanding of 0%.
Around 48% of the company’s stock are held by insiders while 950.8% are held by institutions.
Frequently Asked Questions About Corbus Pharmaceuticals Holding
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.